Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Gout × Clear all

Phase

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2726 Carcinoma, Non-Small-Cell Lung 2278 Breast Neoplasms 2144 Colorectal Neoplasms 1207 Neoplasm Metastasis 1100 Prostatic Neoplasms 1085 Multiple Myeloma 931 Melanoma 927 Ovarian Neoplasms 833 Recurrence 774 Lung Neoplasms 773 Leukemia, Myeloid, Acute 751 Pancreatic Neoplasms 691 Lymphoma, Non-Hodgkin 638 Lymphoma 609 Stomach Neoplasms 573 Carcinoma, Renal Cell 558 Carcinoma, Hepatocellular 543 Leukemia, Lymphocytic, Chronic, B-Cell 475 Squamous Cell Carcinoma of Head and Neck 452 Lymphoma, Follicular 431 Head and Neck Neoplasms 405 Glioblastoma 389 Lymphoma, Large B-Cell, Diffuse 380 Small Cell Lung Carcinoma 360 Leukemia 360 Triple Negative Breast Neoplasms 349 Advanced Solid Tumors 348 Uterine Cervical Neoplasms 346 Urinary Bladder Neoplasms 346

Interventions

Omeprazole 1 Naproxen 1 Febuxostat 1 Colchicine 1 Allopurinol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed

196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡